These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692 [TBL] [Abstract][Full Text] [Related]
38. Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Huang R; Wu R; Lin Y; Zhong X; Ye X; Zhuang X; Liao X J Hypertens; 2022 Oct; 40(10):1918-1926. PubMed ID: 36018222 [TBL] [Abstract][Full Text] [Related]
40. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]